Zykadia for ALK Positive Lung Cancer: New Drug, New Hope
7m
·
GRACEcast ALL Subjects audio and video
·
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
The episode Zykadia for ALK Positive Lung Cancer: New Drug, New Hope from the podcast GRACEcast ALL Subjects audio and video has a duration of
7:22. It was first published
More episodes from GRACEcast ALL Subjects audio and video
Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?
Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.
Management of Rare Kidney Tumors
What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.
Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?
The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.
NanoString Treatment for Kidney Cancer
NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?
Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.